Boyaa Bio: The decline in gross profit margin year-over-year at the company merger level is mainly influenced by three factors.

NightAirdropper · 2026-03-27T10:53:17+00:00

Boyaa Bio stated in response to investor questions that the decline in gross profit margin at the merger level is influenced by factors such as limited product variety and pricing pressure on blood products. The company will optimize its cost structure and improve profitability by enhancing R&D and plasma collection efficiency.

NightAirdropper

2026-03-27 10:53:17

Abstract generation in progress

Securities Daily Network News On March 24, Boya Biology stated in response to investor questions on the interactive platform that the decline in the company’s consolidated gross profit margin year-on-year is mainly influenced by the following three aspects: First, within the scope of consolidation, the product variety of Green Cross in China is relatively small, and the product yield is low, affecting the overall gross profit margin level; Second, the blood product industry is under pressure from supply and demand relationships, leading to product price pressures and a decline in gross profit margin. The company will continue to deeply explore plasma collection efficiency, strengthen the scale effect of plasma cost, and control costs; and enhance research and development efficiency to promote cost structure optimization with a more complete product structure and better product processes; in addition, to empower Green Cross, accelerate the progress of process optimization in Green Cross China, improve product yield, and enhance the company’s profitability.

(Editor Ren Shibi)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.